General Information of Drug (ID: DMFVT43)

Drug Name
E7046 Drug Info
Synonyms
MKLKAQMPKHNQPR-NSHDSACASA-N; UNII-YWY620GU8I; 1369489-71-3; E-7046; YWY620GU8I; ER-886046; SCHEMBL881212; CHEMBL3670685; MolPort-044-561-624; BDBM119448; EX-A1726; ZINC114766778; CS-7559; Benzoic acid, 4-((1S)-1-(((3-(difluoromethyl)-1-methyl-5-(3-(trifluoromethyl)phenoxy)-1H-pyrazol-4-yl)carbonyl)amino)ethyl)-; AC-30338; HY-103088; US8686018, 107; (S)-4-(1-(3-(difluoromethyl)-1-methyl-5-(3-(trifluoromethyl)phenoxy)-1H-pyrazole-4-carboxamido)ethyl)benzoic acid; 4-[(1S)-1-[[3-(difluoromethyl)-1-methyl-5-[3-(trifluoromet
Indication
Disease Entry ICD 11 Status REF
Rectal adenocarcinoma 2B92 Phase 1 [1]
Cross-matching ID
PubChem CID
56944705
CAS Number
CAS 1369489-71-3
TTD Drug ID
DMFVT43

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
16,16-dimethyl-PGE2 DMNF38S Stem cell engraftment QB63.8 Phase 2 [2]
RQ-00000007 (oral) DMMYTRU Pain MG30-MG3Z Phase 2 [3]
ONO-AE1-437 DMCUGI8 Asthma CA23 Phase 2 [4]
BGC-20-1531 DMS2MQ5 Migraine 8A80 Phase 2 [5]
IK-007 DMBLFPN Non-small-cell lung cancer 2C25 Phase 1/2 [6]
TPST-1495 DM3GSB2 Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
ONO-4232 DMO4SD2 Acute heart failure BD10-BD13 Phase 1 [8]
ONO-4578 DME63VK Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
AN0025 DMGSYPY Aggressive cancer 2A00-2F9Z Phase 1 [9]
PGF2alpha DM4XAU7 Solid tumour/cancer 2A00-2F9Z Clinical trial [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin E2 receptor EP4 (PTGER4) TT79WV3 PE2R4_HUMAN Antagonist [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
3 Clinical pipeline report, company report or official report of Avarx.
4 An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo. Pediatr Res. 2004 Oct;56(4):586-90.
5 BGC20-1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009 January; 156(2): 316-327.
6 Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2015 Dec 21;2(1):3-9.
7 Clinical pipeline report, company report or official report of Tempest Therapeutics.
8 ONO-4232, an EP4-selective Agonist, Improves Left Ventricular Diastolic Dysfunction and Ameliorates Acute and Chronic Heart Failure in Animal Models. Circulation. 2012; 126: A15345.
9 AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer. Radiother Oncol. 2023 Aug;185:109669.
10 Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.